Learn more about whether Gilead Sciences, Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor ...

Foster City: Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir-the company’s twice-yearly ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--#GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health ...

16 analysts have shared their evaluations of Gilead Sciences GILD during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...

– Gilead Also Recently Submitted Applications for Lenacapavir for PrEP to the European Medicines Agency That Will Be Reviewed Under Accelerated Assessment Review Timeline – FOSTER CITY, ...

The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release. Gilead Sciences, Inc. recently announced that the FDA accepted its new drug ...

According to the Hebron Fire Department, at around 4:48 p.m. firefighters and troopers were deployed to the scene of Gilead Street for reports of a two-car accident involving a rollover.

Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of Gilead Sciences Inc (Symbol: GILD) were yielding above the 3% mark based on its quarterly dividend ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options begin trading today, for the December 2027 expiration. One of the key data points that goes into the price an option buyer is ...